Prospective study with HEXA-CAF combination in ovarian carcinoma

G. De Palo, R. Demicheli, Pinuccia Valagussa, M. De Lena, E. Villa, F. Di Re, Silvana Pilotti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume5
Issue number3
DOIs
Publication statusPublished - 1981

Fingerprint

Chemotherapy
Cytology
Prospective Studies
Carcinoma
Inspection
X rays
Lymphography
Combination Drug Therapy
Laparoscopy
Cell Biology
Thorax
X-Rays
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

De Palo, G., Demicheli, R., Valagussa, P., De Lena, M., Villa, E., Di Re, F., & Pilotti, S. (1981). Prospective study with HEXA-CAF combination in ovarian carcinoma. Cancer Chemotherapy and Pharmacology, 5(3), 157-161. https://doi.org/10.1007/BF00258473

Prospective study with HEXA-CAF combination in ovarian carcinoma. / De Palo, G.; Demicheli, R.; Valagussa, Pinuccia; De Lena, M.; Villa, E.; Di Re, F.; Pilotti, Silvana.

In: Cancer Chemotherapy and Pharmacology, Vol. 5, No. 3, 1981, p. 157-161.

Research output: Contribution to journalArticle

De Palo, G, Demicheli, R, Valagussa, P, De Lena, M, Villa, E, Di Re, F & Pilotti, S 1981, 'Prospective study with HEXA-CAF combination in ovarian carcinoma', Cancer Chemotherapy and Pharmacology, vol. 5, no. 3, pp. 157-161. https://doi.org/10.1007/BF00258473
De Palo G, Demicheli R, Valagussa P, De Lena M, Villa E, Di Re F et al. Prospective study with HEXA-CAF combination in ovarian carcinoma. Cancer Chemotherapy and Pharmacology. 1981;5(3):157-161. https://doi.org/10.1007/BF00258473
De Palo, G. ; Demicheli, R. ; Valagussa, Pinuccia ; De Lena, M. ; Villa, E. ; Di Re, F. ; Pilotti, Silvana. / Prospective study with HEXA-CAF combination in ovarian carcinoma. In: Cancer Chemotherapy and Pharmacology. 1981 ; Vol. 5, No. 3. pp. 157-161.
@article{5225f6b0922140a0a9f811cb4a24b8dd,
title = "Prospective study with HEXA-CAF combination in ovarian carcinoma",
abstract = "The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9{\%}). CR was recorded in seven patients (22.5{\%}) and PR in six patients (19.3{\%}). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P",
author = "{De Palo}, G. and R. Demicheli and Pinuccia Valagussa and {De Lena}, M. and E. Villa and {Di Re}, F. and Silvana Pilotti",
year = "1981",
doi = "10.1007/BF00258473",
language = "English",
volume = "5",
pages = "157--161",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Prospective study with HEXA-CAF combination in ovarian carcinoma

AU - De Palo, G.

AU - Demicheli, R.

AU - Valagussa, Pinuccia

AU - De Lena, M.

AU - Villa, E.

AU - Di Re, F.

AU - Pilotti, Silvana

PY - 1981

Y1 - 1981

N2 - The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P

AB - The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P

UR - http://www.scopus.com/inward/record.url?scp=0019468139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019468139&partnerID=8YFLogxK

U2 - 10.1007/BF00258473

DO - 10.1007/BF00258473

M3 - Article

VL - 5

SP - 157

EP - 161

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -